New Hampshire · 2026 Regular Session · Bill

SB 465: classifying xylazine as a schedule III controlled drug.

Did not advance Last action April 23, 2026: Inexpedient to Legislate: MA VV 04/23/2026 HJ 11 P. 55

Plain-language summary

SB 465 is a bill introduced in the New Hampshire Senate on November 21, 2025. According to its official title, it concerns: classifying xylazine as a schedule III controlled drug. Primary sponsor: Bill Gannon (Republican). It lists 8 additional sponsors. Most recent recorded action (April 23, 2026): Inexpedient to Legislate: MA VV 04/23/2026 HJ 11 P. 55.

Sponsors

Primary sponsor: Bill Gannon (Republican). 8 co-sponsors.